Recent Investment Analysts’ Ratings Changes for Axsome Therapeutics (AXSM)

Several analysts have recently updated their ratings and price targets for Axsome Therapeutics (NASDAQ: AXSM):

• 11/13/2026 – Axsome Therapeutics had its price target lowered by Morgan Stanley from $249.00 to $223.00. They now have an “equal weight” rating on the stock.
• 11/4/2026 – Axsome Therapeutics had its price target lowered by Mizuho from $284.00 to $272.00. They now have an “outperform” rating on the stock.
• 11/3/2026 – Axsome Therapeutics had its “outperform” rating reaffirmed by Wells Fargo & Company.
• 11/3/2026 – Axsome Therapeutics had its price target lowered by UBS Group from $256.00 to $239.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Axsome Therapeutics had its price target raised by Morgan Stanley from $247.00 to $249.00. They now have an “equal weight” rating on the stock.
• 11/3/2026 – Axsome Therapeutics had its price target lowered by Royal Bank Of Canada from $295.00 to $273.00. They now have an “outperform” rating on the stock.
• 11/3/2026 – Axsome Therapeutics had its price target lowered by Guggenheim from $275.00 to $250.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Axsome Therapeutics had its price target lowered by Robert W. Baird from $246.00 to $220.00. They now have an “outperform” rating on the stock.
• 10/26/2026 – Axsome Therapeutics had its price target lowered by Piper Sandler from $258.00 to $238.00. They now have an “overweight” rating on the stock.
• 10/15/2026 – Axsome Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/14/2026 – Axsome Therapeutics had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 10/8/2026 – Axsome Therapeutics had its price target lowered by Royal Bank Of Canada from $297.00 to $295.00. They now have an “outperform” rating on the stock.
• 9/29/2026 – Axsome Therapeutics had its price target lowered by Deutsche Bank from $280.00 to $267.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Axsome Therapeutics had its price target lowered by Morgan Stanley from $251.00 to $247.00. They now have an “equal weight” rating on the stock.
• 9/25/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 9/23/2026 – Axsome Therapeutics had its price target raised by Truist Financial from $200.00 to $285.00. They now have a “buy” rating on the stock.
• 9/18/2026 – Axsome Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $258.00 price target on the stock.

Axsome Therapeutics Stock Down 1.9%

Shares of NASDAQ:AXSM traded down $2.68 on Friday, reaching $141.69. The company had a trading volume of 972,544 shares, compared to its average volume of 795,626. The firm has a market capitalization of $7.45 billion, a PE ratio of -46.30 and a beta of 0.86. The company has a current ratio of 1.42, a quick ratio of 1.34 and a debt-to-equity ratio of 1.21. Axsome Therapeutics, Inc. has a 52-week low of $123.00 and a 52-week high of $260.19. The firm’s 50 day simple moving average is $172.78 and its 200-day simple moving average is $196.98.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.38. The firm had revenue of $259.69 million during the quarter, compared to analyst estimates of $249.19 million. Axsome Therapeutics had a negative return on equity of 198.73% and a negative net margin of 18.18%. The business’s revenue for the quarter was up 51.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.94) EPS. As a group, analysts expect that Axsome Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of Axsome Therapeutics stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the completion of the sale, the chief operating officer owned 10,000 shares of the company’s stock, valued at approximately $2,086,500. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.60% of the stock is owned by company insiders.

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.